Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Sep 19, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help restore the healthy gut bacteria in young children who have taken antibiotics. Antibiotics are important medicines that fight infections, but they can also disrupt the balance of good bacteria in the gut, which may lead to health issues later in life, such as allergies or obesity. The researchers believe that by collecting a sample of a child’s gut bacteria before they take antibiotics and then giving it back to them afterward through a simple method (mixing it with milk or formula), it might help their gut bacteria recover more quickly and completely.
The trial is looking for healthy infants and toddlers between 1 month and 4 years old. To participate, children should not have taken antibiotics in the past three months and should not have any documented immune system conditions. If eligible, families can expect a straightforward process that aims to help their child's gut health without causing any discomfort. This innovative approach could help improve the long-term health of young children who need antibiotics.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy infants and toddlers 1 month to 4 years of age (regardless of birth mode, sex, or diet (breastmilk, formula, solids, etc.)
- Exclusion Criteria:
- • Child's antibiotic use within 3 months before inclusion in the study
- • Documented immunological condition from the child's pediatrician
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Brunswick, New Jersey, United States
Patients applied
Trial Officials
Maria Gloria Dominguez-Bello, PhD
Principal Investigator
Rutgers Department of Biochemistry & Microbiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported